Port-Site Recurrence Reproduced in the VX-2 Rabbit Carcinoma Model: An In Vivo Model Comparing Laparoscopic Port Sites and Open Incisions by Wilkinson, Neal W. et al.
Port-Site Recurrence Reproduced in the VX-2 Rabbit
Carcinoma Model: An In Vivo Model Comparing
Laparoscopic Port Sites and Open Incisions
JSLS(2001)5:221-226 221
ABSTRACT
Background: The use of advanced laparoscopy remains
controversial in the field of surgical oncology because
the potential for port-site recurrence may violate sound
oncologic principles. Two mechanisms are theorized to
be the cause of port-site recurrences: first, indirect con-
tamination caused by pneumoperitoneum, aerosoliza-
tion, or intraperitoneal spread, and second, direct con-
tamination by physical trocar seeding. 
Methods: A VX-2 carcinoma cell suspension was trans-
ferred under the left renal capsule of 31 rabbits with
either an open flank incision (16) or laparoscopy (15).
Animals were observed for tumor recurrence at the video
port, the working port, and the open incision.
Intraoperative findings and necropsy were used to docu-
ment recurrence.
Results: The open incision technique resulted in local
tumor recurrence in 1/16 animals with 16/16 viable
intraabdominal tumors. The laparoscopic technique
resulted in 0/15 video port-site recurrences and 9/15
working port-site recurrences, with 14/15 viable intraab-
dominal tumors. Recurrence at the laparoscopic working
port occurred more frequently than in the open (P <
0.02) or laparoscopic video port groups (P < 0.007). No
significant difference existed in recurrence between the
open incision and the laparoscopic video port (P > 0.5). 
Conclusions: Laparoscopic port-site recurrences can be
reproduced using the transplantable VX-2 rabbit carcino-
ma model. In the VX-2 model, trocar recurrence is the
result of direct contamination via surgical instrumenta-
tion of viable tumor cells. The effect of the pneumoperi-
toneum or intraperitoneal cytological spillage (indirect
contamination) does not have any effect on trocar recur-
INTRODUCTION
Laparoscopic surgery has proven benefits for the surgical
treatment of numerous benign diseases. Advantages of
laparoscopic surgery include decreased hospital stay,
shortened recovery time, reduction in postoperative
pain, and a more rapid return to regular activities. In
some animal studies, the traumatic effects of surgery
have been found to be immunosuppressive. As a corol-
lary, minimally invasive techniques may preserve impor-
tant immunological reserve of the patient harboring can-
cer.1 Laparoscopic surgery has been used primarily for
staging and palliation of abdominal or thoracic tumors.2-5
To  date, the use of advanced laparoscopy for treat-
ment/resection of cancer is not widely accepted.6-8
Numerous questions exist regarding the extent of resec-
tion, the effects of pneumoperitoneum, and finally port-
site recurrence. Laparoscopic port-site recurrences have
been reported in both benign9 and malignant dis-
eases.10,11 Unfortunately, despite numerous animal stud-
ies and case reports, the etiology of port-site recurrence
is still not well understood. Port-site recurrences are the-
orized to occur via indirect contamination (pneumoperi-
toneum, aerosolization, and intraperitoneal spread) or
direct contamination (physical trocar seeding).12
Understanding the mechanism of port-site recurrence is
imperative if laparoscopy is to be used in cancer treat-
ment.
MATERIALS AND METHODS
Our goal was to establish a minimally invasive method of
achieving VX-2 tumor transfer into the subcapsular renal
Department of Surgery (Drs Wilkinson, Shapiro).
Department of Clinical Investigations (Dr Harvey).
Department of Urology (Drs Stack, Cornum).
Eisenhower Army Medical Center, Fort Gordon, GA 30905, USA.
Address reprint request to: Neal Wilkinson MD, General Surgery Service, Eisenhower
Army Medical Center, MCHF-SD-GSS, Fort Gordon, GA 30905-5650, USA. Telephone:
(706) 787-1153, Fax: (706) 787-2347, E-mail: Neal.Wilkinson@se.amedd.army.mil
© 2001 by JSLS, Journal of the Society of Laparoendoscopic Surgeons. Published by
the Society of Laparoendoscopic Surgeons, Inc.
Neal W. Wilkinson, MD, Andrew J. Shapiro, MD, Stephen B. Harvey, DVM, MS,
Richard S. Stack, MD, Rhonda L. Cornum, PhD, MD
rence. This model can be used to test and improve
laparoscopic techniques to minimize the risk of port-site
recurrence. Until technological advances have eliminated
the risk of trocar recurrences, direct contact between
malignant cells and laparoscopic instruments should be
performed with caution.
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space in rabbits. We made every attempt to achieve zero
operative mortality, minimal postoperative weight loss,
and no extrarenal tumor growth. The Institutional Animal
Care and Use Committee of Eisenhower Army Medical
Center reviewed and approved the protocol.
VX-2 Rabbit Carcinoma
First described in 1940,13 the VX-2 rabbit carcinoma is a
reproducible transplantable malignancy. The VX-2 model
readily produces tumors that penetrate surrounding con-
nective tissues at the primary inoculation site. Invaded tis-
sues exhibit an inflammatory response or desmoplastic
reaction. The tumor forms a white-tan nodule or mass
with centralized necrosis. Histologically, the tumor has
been described as an anaplastic squamous cell carcino-
ma, revealing cells in a sheet-like pattern separated by a
thin stroma consisting of capillaries and inflammatory
cells. The tumor readily metastasizes to lung and lymph
nodes, but metastases to other organs are uncommon.14
Tumor Preparation
To  establish carriers for the VX-2 tumor, male New
Zealand White rabbits weighing 3.5 to 4.5 kg were light-
ly anesthetized with ketamine (30 mg/kg) and xylazine (2
mg/kg) intramuscularly. After shaving and sterilely
preparing the right lateral hindleg, 0.5 mL of a VX-2
tumor suspension previously stored at -150C was inject-
ed into the right hindleg. Approximately 2 weeks later,
the tumor had grown to 2.0 to 2.5 cm in size. After
euthanasia, viable tumor fragments were harvested in a
sterile fashion from the hindleg musculature and placed
in a petri dish containing Supplemented Dulbecco’s
Modified Eagle Medium (Modified DMEM) on ice.
Supplemented DMEM contains DMEM without phenol
red, sodium pyruvate, or sodium bicarbonate (Gibco
BRL), 1X MEM nonessential amino acids (Sigma, St. Louis,
MO, USA), 10% heat inactivated fetal bovine serum (FBS)
(Equitech-Bio, Inc., Ingram, TX, USA), 1 x 10-8M 1, 24-
dihydroxy vitamin-D3 (CalBiochem, LaJolla, CA, USA),
100 U penicillin and 0.1 mg streptomycin per mL (Gibco
BRL), 50 ug/mL gentamicin (Gibco BRL), 1.25 ug/mL fun-
gizone (Gibco BRL), 0.6% sodium bicarbonate (Sigma),
15mM HEPES (Sigma), 0.11 mg/mL sodium pyruvate
(Sigma), and 10-5M ß-Mercaptoethanol (Sigma). 
The tumor was dissected in a sterile fashion into 1 to 2
mm3 fragments. These fragments were placed into a ster-
ile 50-mL tube containing 20 mL Supplemented DMEM,
and allowed to stand on ice for 30 minutes. A tumor cell
suspension was prepared by gently passing the tissue
fragments through a 40-mesh cell dissociation grinder kit
(Sigma). The suspension was centrifuged at 700 RPM for
3 minutes, after which the supernatant was discarded.
The pellet was resuspended with 0.9% PBS and subject-
ed to 2 additional washings. Trypan blue solution 0.5%
was added to an aliquot of cell suspension, and a cell
count by hemocytometer was performed. The resultant
cell solution was prepared to an approximate viable cell
density of 1.14 x 106 cells/mL and placed on ice. This
suspension was then thawed prior to its use.
Operative Technique
Thirty-one male New Zealand White rabbits were anes-
thetized intramuscularly with ketamine (35 mg/kg),
xylazine (4 mg/kg), and glycopyrrolate (0.01 mg/kg IM);
anesthesia was maintained via isoflurane (1-3% in 100%
oxygen) via orotracheal intubation. The abdomen of
each rabbit was shaved and prepared for surgery in a
sterile fashion. Animals were randomized to either an
open (n = 16) or laparoscopic (n = 15) approach group
as described below. All incisions were closed in layers.
Absorbable suture (3-0 Vicryl, Ethicon, Cincinnati, OH)
was used to close the fasciomuscular layer in interrupted
figure of eight fashion. Subcuticular skin closure was
then performed using 4-0 Vicryl (Ethicon, Cincinnati,
OH).
Open Approach
Rabbits in the open group received a 4-cm left flank inci-
sion. Sharp dissection was performed until the left kid-
ney was exposed. The kidney was then elevated into the
wound and a 14-gauge intravenous catheter was used to
inject 1.5 to 2.0 mL of tumor suspension beneath the
renal capsule. All attempts were made to avoid gross
tumor spillage into the peritoneal cavity or flank incision
by placement of laparotomy sponges around the
exposed kidney. No irrigation was used, and the incision
was closed in layers as previously described.
Laparoscopic Approach
Rabbits in the laparoscopic group underwent placement
of a 5-mm trocar at the lower midline using standard
Hassan technique. Carbon dioxide (CO2) pneumoperi-
toneum was established and maintained at 8 to 10 mm
Hg. A pediatric cystoscope was inserted through the 5-mm trocar and used for a video port (VP). Manual exter-
nal manipulation along with blunt and sharp dissection
facilitated the laparoscopic exposure of the left kidney.
Once the lower pole was identified, a second disposable
3-mm port was placed under visual guidance to serve as
a working port (WP). A 14-gauge needle was inserted via
the WP and advanced under the left renal capsule. Once
appropriately positioned, 1.5 to 2.0 mL of the tumor cell
suspension was injected through this needle. Within the
limitations of laparoscopy, all attempts were made to
reproduce the open technique. The WP was removed
under direct visualization. Gentle external pressure
ensured that the pneumoperitoneum was not released
from the WP site. The VP was used to release the pneu-
moperitoneum, after which the VP was removed. No
effort was made to limit the release of gas or fluid from
either port after the VP was removed. All attempts were
made to avoid gross tumor spillage into the peritoneal
cavity or either port incision. No irrigation was used, and
the incision was closed in layers as previously described.
Postoperative Care
Immediately after surgery, all animals were administered
buprenorphine (0.02 mg/kg) intramuscularly to control
postoperative pain. Following tumor implantation, a sec-
ond exploration was performed to confirm successful
tumor transplantation between postinjection day 7 and
14. Detailed intraoperative evaluation was performed to
document renal and extra-renal tumor growth. Extrarenal
sites of most importance were open flank and trocar inci-
sions. Time of first incisional or port-site recurrence was
documented in each case. Animals were euthanized if no
renal tumor was present, tumor burden was excessive, or
6 weeks had elapsed following confirmation of success-
ful tumor transplant. The final postmortem examination
was performed to confirm that no local recurrence was
missed.
Statistical Method
Differences between the various groups: WP, VP, and
open incision were evaluated using Fisher’s exact test.
Results were considered statistically significant at P < 0.05. 
RESULTS 
Thirty-one rabbits underwent VX-2 tumor transfer with
no operative deaths. Successful VX-2 tumor transfer
beneath the kidney was confirmed in 30 animals. The
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open incision technique resulted in a renal tumor in 16
of 16 injections. The open technique resulted in a local
incisional recurrence in 1/16 animals. The laparoscopic
technique gave rise to 14 renal tumors out of 15 injec-
tions. Only 1 animal failed to produce a renal tumor. The
1 animal that failed to produce a viable renal tumor did
not have either video or working port-site recurrence.
Failure to produce a baseline renal tumor may have been
due to improper handling of the VX-2 media; thus, only
animals with viable renal tumors were used in statistical
analysis. As such, the laparoscopic technique resulted in
0/14 video port-site recurrences and 9/14 working port-
site recurrences (Figure 1). Recurrence at the laparo-
scopic working port occurred more frequently than in
the open group (P < 0.02) or laparoscopic video port (P
< 0.007). No significant difference existed in recurrence
between open incision and laparoscopic video port (P >
0.5). 
All animals were confirmed to have recurrence at inci-
sion or port sites by intraoperative exploration or necrop-
sy, or both (Figure 2). Computed tomography (CT)
scanning was initially used to document recurrence but
was found to be unreliable; many animals without CT
evidence of local disease were found on later exploration
Figure 1. Recurrence rate by the various techniques used: open
and laparoscopic. Open technique had incisional recurrence rate
of 6%. In the laparoscopic groups the working port (WP) had a
64% recurrence rate, but the video port (VP) had a 0% recurrence
rate.Port-Site Recurrence Reproduced in the VX-2 Rabbit Carcinoma Model: An In Vivo Model Comparing Laparoscopic Port Sites and
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to have local disease. The mean interval to confirmed
positive recurrence was 12.8 days with a standard error
of 1.8. The mean interval to confirmed negative recur-
rence was 29.1 days with a standard error of 3.6. Animals
in all groups that failed to demonstrate recurrence were
observed for a longer period of time to ensure that a sub-
clinical recurrence was not missed. No recurrences
occurred after 20 days (Table 1).
DISCUSSION
Surgical oncologists have resisted incorporating
laparoscopy into the management and treatment of the
cancer patient. Presently, this tool remains underutilized
except in selected indications: staging and palliation.
Numerous concerns remain: whether to include the
extent of resection, effects of CO2 pneumoperitoneum,
and finally trocar recurrences. Data will be forthcoming in
the near future regarding safety and efficacy of laparo-
scopic resection of colorectal cancers.15 Other malignan-
cies will await further trials well into the future. 
The pathogenesis of trocar recurrences remains an open
question. Indirect contamination of the trocar site may
occur when free intraperitoneal cancer cells are pushed
from the abdominal cavity to the trocar site via a pressure
gradient. This is also referred to as the “chimney” effect.
To  study this phenomenon, laparoscopists have used
intraperitoneal injection of tumor cells in various animal
models.16 These models assume that cancer cells are free
floating in the peritoneal cavity, and thus reproduce car-
cinomatosis or stage IV disease. Interestingly, most
patients with intraabdominal cancer have negative cytol-
ogy at time of diagnosis and treatment. For example, in
colorectal and pancreatic cancer only 1 in 3 patients has
positive cytology; furthermore, those with positive cytol-
ogy tend to have more advanced disease (Table 2).17-20
The intraperitoneal injection models have implications
for advanced disease states, but may not accurately
model laparoscopy in cancer patients who present with
stage I, II, or III disease. Furthermore, this theory fails to
explain how trocar recurrences have occurred in thora-
coscopic and gasless laparoscopy.13
Direct contamination of the trocar site may occur when
surgical instruments convey cancer cells from the abdom-
inal cavity to the port-site.16 This theory requires that
viable cancer cells undergo iatrogenic transfer and depo-
sition into the subcutaneous tissue at the port site. The
cancer cells may arise from direct contact with a solid
tumor or may be picked up in surgically contaminated
Figure 2. Hematoxylin and eosin (H&E) section demonstrating
trocar recurrence in the abdominal wall. Note tumor is small and
contained within the muscular fibers. All tumors presented with-
in 20 days of contamination.
Table 1.
Observation Time Between Different Groups.
Interval(mean) Range
Open (all) 30.9 days 7-49
Laparoscopic (all) 16.3 7-33
Wound Recurrence(lap) 12.8 7-20
No Wound Recurrence(lap) 21.6 9-33
No Wound Recurrence(open) 31.1 7-49
Table 2.
Comparison of Colorectal and Pancreatic Cancers.
Positive peritoneal % with stage IV disease
cytology
Colon  3% to 30% 70% to 100%
Pancreas 12% to 22% 100%peritoneal fluid. To best reproduce the direct contamina-
tion model, cytology negative, solid tumor models are
required. Solid tumor models are harder to reproduce and
as such animal models are few in number (Table 3).21-25
Most of these models require that tumor implantation be
followed by surgical manipulation. Multiple surgical pro-
cedures, tumor variability, and surgeon experience can
affect trocar recurrence. Simplified solid organ models are
still needed to study the trocar recurrence phenomena. 
The VX-2 rabbit model can produce a solid organ malig-
nancy and results in reproducible incisional and trocar
recurrences. This model demonstrated an open incision-
al recurrence rate of 6%. This is far greater than the his-
torical incisional recurrence rate found in human col-
orectal cancers, which falls between 0.6% and 0.8%.26,27
This ten fold increase in open recurrence rate attests to
the aggressive nature of the VX-2 tumor. More important
than the open incisional recurrence rate is the laparo-
scopic trocar recurrence rate. In the colorectal literature,
the incidence of laparoscopic trocar recurrences has
been reported to be between 0% and 21%, but recent
series place the incidence between 0% and 2%.13,15,16 In
the VX-2 model, the trocar recurrence rate was 64% at
the WP. This high recurrence rate at the WP makes this
model ideal for testing and perfecting surgical tech-
niques. By reproducing the direct contamination model
at 1 trocar, efforts can be focused on how to limit sub-
cutaneous implantation. New trocar removal techniques
and local treatments (surgical or chemical) can be tested
using this model. A second key finding was the 0% VP
recurrence rate. If trocar recurrences were the result of
indirect contamination from the intraperitoneal VX-2
cells, then the VP and WP would be equally affected. Of
note, the pneumoperitoneum was released primarily via
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the VP. When the animals underwent formal exploration,
carcinomatosis was not seen. The VX-2 model did not
produce intraperitioneal contamination to any clinically
significant degree. The CO2 pneumoperitoneum did not
have any independent effect on trocar recurrence. This
implies that diagnostic laparoscopy is safe and should
result in minimal trocar recurrence risk in the cancer
patient without positive cytology or stage IV disease.
Direct tumor contact was the deciding factor between
recurrence and recurrence-free ports. The ability to
reproduce a trocar recurrence without contaminating the
peritoneal cavity makes the model more applicable to
human cancers. 
CONCLUSION
VX-2 trocar recurrence is the result of direct contamina-
tion between the surgical instruments and viable tumor
cells. VX-2 animal model reproduces trocar recurrence in
64% of working ports but 0% of video ports. The effect
of indirect contamination, pneumoperitoneum, or
intraperitoneal cytological spillage did not have any
effect on recurrence rate. This negative cytology, solid
tumor model can be used to improve laparoscopic tech-
niques and minimize trocar recurrences. At present,
malignant cell contact with laparoscopic instruments
should be performed with caution. 
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